Sense Campaign - Left Out Of Life
22 April 2021 / Posted in: Information, Support
Sense have launched this campaign, which is about taking action to tackle loneliness among disabled people and making society more inclusive. The campaign is calling for more investment in services to tackle loneliness and offer mental health support for disabled people. Sign their pledge and play your part in making society more inclusive.
BBC News Survey - How Covid-19 has Affected Deaf and Disabled People
21 April 2021 / Posted in: Information, Support
BBC News is carrying out a survey to understand how Covid-19 has affected deaf and disabled people. They are trying to reach as many people as possible to get the biggest, most detailed picture they can.
Evrysdi Continues to Improve Motor Function and Survival in Babies with SMA Type 1
19 April 2021 / Posted in: Treatments & Research
Roche has shared new two-year data from part 2 of its FIREFISH study. FIREFISH is assessing Evrysdi™ (risdiplam) in the treatment of infants aged 1-7 months at enrollment, with symptomatic SMA Type 1. The data build upon one-year findings from FIREFISH Part 2, which measures the ability to sit without support for at least five seconds as its primary endpoint.
Zolgensma Treatment for SMA Type 1 in the UK - Live Webinar with Experts
15 April 2021 / Posted in: Information, Treatments & Research, Support
On Wed 21st April at 5.30pm, this webinar with Prof. Francesco Muntoni (Consultant Paediatric Neurologist, GOSH), Dr Anne-Marie Childs (Consultant Paediatric Neurologist, Leeds) and Fiona Marley (Head of Highly Specialised Commissioning, NHS England), will be hosted by Martyn Sibley on the SMA UK Facebook and Twitter channels. You can send in your questions beforehand.
SMA UK Responds to NICE’s Evaluation Consultation for Access to Zolgensma
13 April 2021 / Posted in: Treatments & Research
Last week, we supported NICE’s recommendations. We acknowledged that no current evidence or modelling was presented to demonstrate that Zolgensma could also provide health benefits for a proportion of children with SMA Type 2 and 3 and urged Novartis Gene Therapies to continue to work to address this gap in access to the treatment.
Have your say on where to install Changing Places Toilets in England
09 April 2021 / Posted in: Information, Support
If you use Changing Places toilets, or need to use them, you can add your voice to the UK’s biggest consultation about these vital facilities. By doing the 10-minute survey, you’ll help inform where, and in which buildings, these facilities are needed the most in England. Survey closes: 23rd April.
Scholar Rock Announces Results from TOPAZ Phase 2 Trial in SMA Types 2 and 3
08 April 2021 / Posted in: Treatments & Research
Apitegromab (also known as SRK-015) aims to reverse or restrict the muscle atrophy and weakness experienced by people living with SMA. Topaz is a clinical trial designed to assess the safety and efficacy of apitegromab in people living with SMA Types 2 and Type 3. The 12-month data announced yesterday by Scholar Rock demonstrate early therapeutic potential.
DCP Campaign - Call for a Recovery Plan
07 April 2021 / Posted in: Information, Support
Join this campaign from the Disabled Children's Partnership by emailing the Government to share your experiences and call on them for a Covid19 recovery plan for disabled children, young people and families.
Living With SMA Podcast - New Episode Available!
07 April 2021 / Posted in: Information, Support
The next episode of our Living With SMA podcast is available to listen to now! In 'My Experience of Home Adaptations', SMA UK Host Josh Wintersgill talks to Julian Fiorentini, who shares his personal journey from school days, through to living in a care home and his experience of making adaptations to his home, as an adult.
Results of SMA Europe’s 2nd Pan-European Survey on Patient Expectations Published
30 March 2021 / Posted in: Information, Treatments & Research
Completed by 1,474 people from 26 European countries, this study confirms what we have been saying in the UK in particular that stabilisation of someone’s SMA and even minor changes in their ability have meaningful impacts on daily life. It’s now summarised on the SMA Europe website with a link to the full publication.
